Alcon Research

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alcon Research sits in the top decile of US sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count).

275 total trials 5 currently recruiting 248 completed later-stage tilt top decile by trial count

Alcon Research: 275 sponsored US clinical trials, 5 recruiting.

Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.

Top-decile sponsor footprint

Alcon Research ranks in the top decile of sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

248 of 266 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

275 total, page 6 of 6

COMPLETED Phase 3

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

NCT00333255

TERMINATED Phase 3

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00333216

COMPLETED Phase 3

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

NCT00299507

COMPLETED NA

Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles

NCT00383201

COMPLETED Phase 3

Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus

NCT00333268

COMPLETED NA

Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients

NCT00382603

COMPLETED NA

Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses

NCT00382902

COMPLETED NA

Evaluation of an Investigational Multi-Purpose Disinfecting Solution for Care of Soft Contact Lenses

NCT00382681

TERMINATED Phase 3

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00307398

TERMINATED Phase 3

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

NCT00065728

COMPLETED Phase 4

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

NCT00061503

COMPLETED Phase 3

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994

COMPLETED Phase 3

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00061529

COMPLETED Phase 3

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT00061542

COMPLETED Phase 2

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT00051194

COMPLETED Phase 3

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

NCT00041483

COMPLETED Phase 3

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

NCT00047541

COMPLETED Phase 3

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142

COMPLETED Phase 3

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

NCT00051155

COMPLETED Phase 3

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

NCT00047515

COMPLETED Phase 3

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

NCT00047528

COMPLETED Phase 2

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

NCT00346866

COMPLETED Phase 3

Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98

NCT00047593

COMPLETED Phase 3

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181

COMPLETED Phase 2

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719

← Previous Page 6 of 6

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 23
Phase 3 47
Phase 4 40

Where Alcon Research enrollment is open (later-stage tilt)

5 recruiting of 275 indexed (2% open); 248 completed (90%).

Phase mix: 87 late (III/IV) vs 28 early (I/II) (later-stage heavy).

Top condition: Cataract (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alcon Research: open-pipeline peers nationwide

Peers matched on 275 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15%20%25% Total trials Recruiting share Alcon ResearchBoston Scientific CorporationRegeneron PharmaceuticalsSWOG Cancer Research NetworkNovartisLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLexicon PharmaceuticalsSociété des Produits Nestlé (SPN)Eisai
Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 275 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

What to do with this Alcon Research page

275 registered trials is a research-attention snapshot, not an endorsement of Alcon Research or any single study.

  • 5 of Alcon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cataract is the condition Alcon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alcon Research pipeline card: 275 registered trials from official public datasets.Report a data error.